dm+d

Unassigned

New Medicines

Aggression/agitation associated with Alzheimer's disease

Information

New molecular entity
Otsuka
Avanir

Development and Regulatory status

Discontinued
Discontinued
Phase III Clinical Trials
May 22Otsuka has decided not to file a marketing authorisation application for AVP-786 [17].

Category

Deuterium-modified dextromethorphan (NMDA antagonist/sigma agonist) + quinidine (CYP2D6 inhibitor)
Behavioral and psychiatric symptoms develop in as many as 60% of community-dwelling people with dementia and in more than 80% of patients living in nursing homes; the lifetime risk of such complications approaches 100% [1].
Aggression/agitation associated with Alzheimer's disease
Oral